Intramuscular plasmid DNA injection can accelerate autoimmune responses

Abstract

We have investigated if the administration of plasmid vectors engineered for gene delivery into mammalian muscle induced the production of anti-double stranded (ds) DNA and anti-nuclear autoantibodies in normal and autoimmunity-prone mouse models. In normal mice, repeated injection of plasmid DNA did not trigger an anti-DNA response. The presence of eukaryotic transcription factor binding sites in plasmid vectors did not increase autoantibody formation in these animals. In contrast, repeated injection of such plasmids in autoimmunity-prone MRL/MpJ mice caused a significant increase in both anti-dsDNA and anti-nuclear antibody levels. Thus the repeated administration of bacterial plasmids containing eukaryotic promoter elements may induce immune responses with generation of antibodies cross-reacting not only with the mammalian DNA, but also with nuclear antigens. The potential for iatrogenic autoimmunity in susceptible individuals should be considered.

Main

Nucleic acid vaccines and gene therapy using intramuscular injection of plasmid DNA has entered clinical trials and may ultimately find a widespread clinical use.1,2 It is, therefore, important to identify and eliminate safety concerns associated with plasmid DNA injection, such as the potential for chromosomal integration, germ line transfer, induction of immune tolerance and plasmid immunogenicity.3,4

Plasmid DNA has an adjuvant property, which partially accounts for why genetic vaccines generate such effective immunity. This immunostimulatory property of plasmid DNA is contained within short unmethylated immunostimulatory sequences (ISS), consisting of a CpG dinucleotide flanked by two 5′ purines and two 3′ pyrimidines.5 ISS stimulate B cell division in vivo, activate macrophages to produce nuclear factor kappa B (NF-κB) and tumor necrosis factor alpha (TNF-α) mRNA, which are produced during inflammatory responses.6 Furthermore, ISS induce the production of cytokines and promote a helper T cell type 1 (TH1) response.7 This unique ability of plasmid-based DNA vaccines to stimulate cellular and humoral immune responses has led to novel vaccine preparations that are as effective as traditional products.8

However, an undesirable consequence of using plasmid DNA for vaccination or gene delivery may be the stimulation of potentially dangerous inflammatory and immune responses. The eukaryotic promoters within plasmid expression cassette contain transcription factor binding sites, and this combination – of ISS, plasmid DNA and bound transcription complex – could form a strong antigen-hapten combination. Potentially, injection of plasmids containing ISS may, under specific circumstances, initiate or increase anti-DNA and antinuclear autoimmune responses. Such antibodies are diagnostic markers for autoimmune diseases and the possibility of DNA injection triggering development of such autoimmunity should be considered.

The work described here examines the ability of plasmid DNA to induce systemic anti-DNA and anti-nuclear responses in normal (BALB/c) and autoimmunity-prone MRL/MpJ mice. This strain is characterised by low-level autoantibody production to double-stranded DNA9 and is bred as a control for MRL/MpJ-Faslpr mice. The latter strain is a model for systemic lupus erythematosus-like autoimmune syndromes.

Different types of plasmids, all containing ISS but with various combinations of prokaryotic and eukaryotic sequences were used to establish if the sequences contained within these vectors could influence the production of autoantibodies in BALB/c mice. One type (pBS) had no mammalian DNA sequences (bacterial plasmid) and the second type (pXAV and pcDNA3) had combinations of mammalian promoter/enhancer elements typical for plasmids used in nucleic acid vaccination and gene therapy trials. It has been shown that multiple injection of plasmid vaccine is required to generate protective immunity against pathogens in different species8,10 and similarly, repeated administration of plasmids may be needed in many gene therapy applications. Therefore, to mimic these gene delivery protocols, 25 μl of plasmid (2 mg/ml) were administered via single or multiple injections in the tibilais anterior muscle. Intraperitoneal injection was also used as a delivery route.

Following injections the serum titers of anti-double stranded DNA (dsDNA) antibodies were measured using a calf thymus dsDNA ELISA. None of the three plasmids (pBS, pXAV or pcDNA3) injected four times at 2-week intervals caused an increase in anti-dsDNA antibody levels compared with saline-injected controls. Moreover, injection of the pcDNA3 by an i.p route also had no effect on anti-dsDNA antibody production in this model (Figure 1a).

Figure 1
figure1

Generation of anti-dsDNA antibody production in BALB/c and MRL/MpJ mice injected with plasmid DNA vectors. The three plasmid DNA vectors were used in the experiments shown in (a): pBluescript (pBS, Stratagene, La Jolla, CA, USA; with no eukaryotic elements), pcDNA3E (p3E) and pXAV (containing the CMV promoter myosin light chain 1/3 enhancer +/− the neomycin selection gene respectively25). Endotoxin-free plasmid DNA was prepared from transformed DH5α cells (Life Technologies, Paisley, UK) using a method, which has been described previously.7 Four-week-old female BALB/c and MRL/MpJ mice were obtained from Harlan UK Ltd, Blackthorn, UK; and kept under standard conditions. All procedures were carried out in accordance with Home Office Guidelines. Anaesthesia was induced using fluothane (Rhone Merieux, Harlow, UK) and each group of mice (n = 7) received 25 μl of specific plasmid in saline solution (2 mg/ml) i.m., in the tibilais anterior muscle. In the multiple injection groups this was followed by three further injections at 2-week intervals (at 6, 8 and 10 weeks of age). An additional group of BALB/c mice received multiple intraperitoneal injections of plasmid DNA over the same sequence (a, i.p.). MRL/MpJ mice (n = 7) were injected with pcDNA3E or with saline (b). Two weeks after the final injection, mice were killed, blood immediately removed by cardiac puncture and sera prepared. Serum samples from plasmid-injected BALB/c, MRL/MpJ and MRL/MpJ-Faslpr (positive control) mice were assayed in triplicates for double-stranded DNA antibodies using a Diastat anti-dsDNA kit (Shield Diagnostics, Dundee, UK). Samples were diluted 1 in 100, in PBS containing Triton X-100 (0.01%) and bovine serum albumin (5% w/v) and sodium azide (0.5% w/v). 100 μl of each sample was added to 96-well microtitre plates coated with calf thymus dsDNA, and incubated for 60 min at room temperature. Wells were washed three times in phosphate buffered saline (PBS)/Tween 20 (0.1% w/v), and incubated for 30 min with goat anti-mouse polyvalent immunoglobulin AP conjugate diluted 1 in 3000 in PBS/Tween 20. Samples were washed three times in wash buffer before adding 100 μl of substrate solution (phenolphthalein monophosphate, Mg2+, in buffer solution). Reactions were incubated for 30 min at room temperature, followed by addition of 100 μl of stop solution. Absorbance was measured on a microtitre plate reader at O.D. 550 nm. Significant differences between mean O.D. values were determined using an unpaired t test, with significance set as P 0.05.

In MRL/MpJ mice, the titer of anti-dsDNA and anti-nuclear immunoglobulins in the sera was measured following single and multiple injections of plasmid using the same protocol as for the experiment with BALB/c mice. In this model, the mean serum level of anti-dsDNA antibodies in multiple plasmid-injected MRL/MpJ mice was significantly higher than in the saline-injected group (0.68 ± 0.11 versus 0.42 ± 0.06, P < 0.05) (Figure 1b). This indicated that i.m. injection of bacterial plasmid DNA could increase the production of antibodies with affinity for mammalian dsDNA.

The sera from MRL/MpJ animals were then analysed for antibodies, which cross-reacted with epitopes in cell nuclei, using a qualitative fluorescence assay. The positive control serum from a MRL/MpJ.Faslpr mouse gave a strong pattern of immunoreactivity against the cell nucleus (Figure 2a). Six of the seven MRL/MpJ mice injected with plasmid had antibodies, which reacted with the cell nuclei of HEp-2 cells. Moreover, the patterns of immunoreactivity revealed great variability of antinuclear antibodies that were generated in response to plasmid injection. Three sera gave a fine speckled granular pattern (Figure 2c), a fourth serum generated a nucleolar pattern of immunofluorescence (Figure 2d) and two sera gave a weaker fine-speckled pattern of staining.

Figure 2
figure2

Detection of anti-nuclear antibodies in the sera of MRL/MpJ mice injected with plasmid DNA. Sera from the MRL/MpJ group injected with pcDNA3E were further analysed for anti-nuclear antibodies (ANA) using an indirect immunofluoresence assay routinely used for clinical diagnosis. Acetone-fixed human larynx carcinoma (HEp-2) cells (Bion Inc., IL, USA) were used to detect ANA, and the staining pattern in cell nuclei was identified using a modified version of a method, which has been previously described.26 Serum samples were diluted 1 in 40 in PBS with sodium azide (0.01% w/v). 20 μl of diluted MRL/MpJ sera were added to HEp-2 slides, and incubated for 30 min at room temperature in a humidified chamber. Slides were rinsed once in PBST followed by two 10-min washes. 10 μl of FITC-conjugated rabbit anti-mouse immunoglobulins (Dako A/S, Glostrup, Denmark), diluted 1 in 40 in PBST, were added and slides incubated for 30 min in a humidified chamber. Slides were mounted (in 70% glycerol, 2.5% DABCO in PBS, pH 8.3) and analysed using an epifluorescence microscope (magnification ×400) with filters optimized for FITC detection. (a) Positive control anti-nuclear antibody immunoreactivity with serum from a 15-week-old MRL/MpJ-Faslpr mouse. (b) A typical negative pattern of serum immunoreactivity found in saline-injected MRL/MpJ mice. (c and d) Two typical patterns of ANA immunoreactivity found in MRL/MpJ mice injected with plasmid showing fine-speckled granular and anti-nucleolar patterns of immunoreactivity, respectively.

This immunoreactivity was in a marked contrast to the negative staining in control sera from a saline-injected MRL/MpJ mice (shown in Figure 2b). Of the seven sera from MRL/MpJ mice injected with saline, only two generated a weak pattern of immunoreactivity on HEp-2 cells (data not shown).

In contrast to the multiple injections, the single injection of 25 μl of plasmid (2 mg/ml) in the tibilais anterior muscle of MRL/MpJ mice did not result in any significant changes in autoantibody levels as compared with controls (data not shown).

We have shown that in normal mice, repeated injection of plasmid DNA typical of a plasmid immunisation regime does not trigger an autoimmune response. This is in agreement with results by others showing no or only very low-level anti-DNA responses induced in normal animals in similar paradigms.11,12,13 Furthermore, the inclusion of eukaryotic TF binding sites did not increase the risk of autoantibody formation in immunologically naive mice. However, multiple plasmid injections in the autoimmunity-prone MRL/MpJ mice caused a significant increase of anti-DNA antibodies, which was accompanied by an increase in the number of sera containing anti-nuclear antibodies. Thus, repeated administration of bacterial plasmids containing eukaryotic promoter elements may stimulate immune responses with antibodies reacting not only with the mammalian DNA, but also with endogenous cell nuclear antigens.

Sera from autoimmune systemic lupus erythematosus (SLE) patients14,15 and a small proportion of the normal population16,17,18,19 contain anti-DNA antibodies recognising epitopes present on mammalian DNA and we have shown here that in predisposed mice, this mechanism can be augmented in response to repeated overload with bacterial plasmid DNA.

The structure of the variable regions of SLE autoantibodies against double-stranded DNA indicates that they are produced in response to an antigen-selective stimulation.20 Furthermore, the combination of ISS, plasmid DNA and bound transcription complex may form a strong antigen-hapten combination and such complexes may be released from intracellular compartments in response to muscle damage and inflammation caused by the DNA injection procedure. There is mounting evidence that anti-DNA antibodies are also produced in response to DNA–protein complexes rather than naked DNA, as combinations of DNA with various DNA- binding proteins including nucleosomal peptides21 and non-self antigenic peptides22 have been shown to trigger anti-DNA responses.

The recent animal model data indicated that anti-DNA antibodies promote pathological mechanisms in chronic inflammatory disorders23 and bacterial DNA can exacerbate autoimmune responses.24 However, it must be stressed that the clinical implications of the plasmid-induced autoimmune phenomenon described here are not clear. In addition to the potential safety considerations, binding of antibodies to plasmid DNA may result in rapid elimination or sequestration of DNA and the development of autoantibodies could also decrease the efficacy of subsequent applications of nucleic acids as vaccines or gene therapy vectors.

References

  1. 1

    Gurunathan S, Klinman DM, Seder RA . DNA vaccines: immunology, application, and optimization Annu Rev Immunol 2000 18: 927–974

  2. 2

    MacColl GS, Goldspink G, Bouloux PMG . Using skeletal muscle as an artificial endocrine tissue J Endocrinol 1999 162: 1–9

  3. 3

    Parker SE et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits Hum Gene Ther 1999 10: 741–758

  4. 4

    Górecki DC, Simons JP . The dangers of DNA vaccination Nat Med 1999 5: 126

  5. 5

    Pisetsky DS . Immunostimulatory DNA: a clear and present danger? Nat Med 1997 3: 829–831

  6. 6

    Stacey KJ, Sweet MJ, Hume DA . Macrophages ingest and are activated by bacterial DNA J Immunol 1996 157: 2116–2122

  7. 7

    Wells KE et al. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle FEBS Lett 1997 407: 164–168

  8. 8

    Davis HL, McCluskie MJ, Gerin JL, Purcell RH . DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines Proc Natl Acad Sci USA 1996 93: 7213–7218

  9. 9

    Jackson mouse database 2000 http://jaxmice.jax.org/index.shtml

  10. 10

    Sedegah M, Hedstrom R, Hobart P, Hoffman SL . Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein Proc Natl Acad Sci USA 1994 91: 9866–9870

  11. 11

    Jiao S et al. Direct gene transfer into nonhuman primate myofibers in vivo Hum Gene Ther 1992 3: 21–33

  12. 12

    Katsumi A et al. Humoral and cellular immunity to an encoded protein induced by direct DNA injection Hum Gene Ther 1994 5: 1335–1339

  13. 13

    Mor G et al. Do DNA vaccines induce autoimmune disease? Hum Gene Ther 1997 8: 293–300

  14. 14

    Karounos DG, Grudier JP, Pisetsky DS . Spontaneous expression of antibodies to DNA of various species origin in sera of normal subjects and patients with systemic lupus erythematosus J Immunol 1988 140: 451–455

  15. 15

    Wu ZQ, Drayton D, Pisetsky DS . Specificity and immunochemical properties of antibodies to bacterial DNA in sera of normal human subjects and patients with systemic lupus erythematosus (SLE) Clin Exp Immunol 1997 109: 27–31

  16. 16

    Devlam K et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood-donors Clin Exp Rheumatol 1993 11: 393–397

  17. 17

    Tan EM et al. Range of antinuclear antibodies in ‘healthy’ individuals Arthr Rheum 1997 40: 1601–1611

  18. 18

    Zarmbinski MA, Messner RP, Mandel JS . Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus J Rheumatol 1992 19: 1380–1384

  19. 19

    Rosenberg AM et al. Prevalence of antinuclear antibodies in a rural population J Toxicol Environ Health A 1999 57: 225–236

  20. 20

    Eilat D, Naparstek Y . Anti-DNA autoantibodies: a puzzle of autoimmune phenomena Immunol Today 1999 20: 339–342

  21. 21

    Kaliyaperumal A, Mohan C, Wu W, Datta SK . Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus J Exp Med 1996 183: 2459–2469

  22. 22

    Moens U et al. In vivo expression of a single viral DNA-binding protein generates systemic lupus erythematosus-related autoimmunity to double-stranded DNA and histones Proc Natl Acad Sci USA 1995 92: 12393–12397

  23. 23

    Williamson RA et al. Ant-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis Proc Natl Acad Sci USA 2001 98: 1793–1798

  24. 24

    Tsunoda I et al. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA Brain Pathol 1999 9: 481–493

  25. 25

    Novo FJ, Górecki DC, Goldspink G, MacDermot KD . Gene transfer and expression of human alpha-galactosidase from mouse muscle in vitro and in vivo Gene Therapy 1997 4: 488–492

  26. 26

    Humbel RL . Detection of antinuclear antibodies by immunofluorescence In: Van Vendrooij WJ, Maini RN (eds) Manual of Biological Markers of Disease: Methods of Autoantibody Detection Kluwer Academic Publishers: London 1993 pp A2.1–A2.16

Download references

Author information

Correspondence to DC Górecki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

MacColl, G., Bunn, C., Goldspink, G. et al. Intramuscular plasmid DNA injection can accelerate autoimmune responses. Gene Ther 8, 1354–1356 (2001) doi:10.1038/sj.gt.3301537

Download citation

Keywords

  • plasmid vector
  • anti-DNA antibodies
  • anti-nuclear antibodies
  • autoimmunity

Further reading